Luke Miels had been chief executive of GSK for only six months when he announced the biggest bet of his career. This week’s $10.6bn megadeal with US cancer biotech Nuvalent was the UK pharma group’s largest biotech acquisition in more than 25 years.
卢克•米尔斯(Luke Miels)出任葛兰素史克(GSK)首席执行官才六个月，就宣布了其职业生涯中最大的一笔赌注。本周与美国癌症生物技术公司Nuvalent达成的这笔106亿美元的巨额交易，是这家英国制药集团25年来规模最大的生物科技收购。
您已阅读5%（370字），剩余95%（6967字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。